Answers are grounded in this paper and cite their sources.
We used meropenem to successfully treat a patient with bacteremia due to ceftazidime-avibactam-resistant, meropenem- susceptible Klebsiella pneumoniae that carried mutant blaKPC-3. Meropenem was bactericidal against ceftazidime-avibactam- resistant K pneumoniae isolates in vitro. Nevertheless, the role of carbapenems in treating such infections remains uncertain, because meropenem resistance is selected readily during passage experiments.
No takes yet. Share an insight, caveat, or question.
Shields et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: